Endoscopic and Histologic Response and Remission in Inflammatory Bowel Disease Patients Initiating Vedolizumab

被引:2
|
作者
Christensen, Britt [1 ]
Rubin, David T. [1 ]
Goeppinger, Sarah [1 ]
Colman, Ruben J. [1 ]
Yarur, Andres [1 ]
Hirsch, Ayal [1 ]
Bocheneck, Ashley [1 ]
Wichmann, Alana [1 ]
Sakuraba, Atsushi [2 ]
Cohen, Russell [1 ]
Siddiqui, Dania [1 ]
机构
[1] Univ Chicago Med, Chicago, IL USA
[2] Univ Chicago, Chicago, IL 60637 USA
来源
关键词
D O I
10.14309/00000434-201510001-01843
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
1843
引用
收藏
页码:S783 / S784
页数:2
相关论文
共 50 条
  • [21] Correction to: Vedolizumab Concentrations Are Associated with Long-Term Endoscopic Remission in Patients with Inflammatory Bowel Diseases
    Andres J. Yarur
    Alexandra Bruss
    Snehal Naik
    Poonam Beniwal-Patel
    Caroline Fox
    Anjali Jain
    Brandon Berens
    Amir Patel
    Ryan Ungaro
    Bayda Bahur
    Marla Dubinsky
    Daniel J. Stein
    [J]. Digestive Diseases and Sciences, 2019, 64 : 3674 - 3675
  • [22] Immunological Variables Associated With Clinical and Endoscopic Response to Vedolizumab in Patients With Inflammatory Bowel Diseases
    Coletta, Marina
    Paroni, Moira
    Alvisi, Maria Francesca
    De Luca, Matilde
    Rulli, Eliana
    Mazza, Stefano
    Facciotti, Federica
    Lattanzi, Georgia
    Strati, Francesco
    Abrignani, Sergio
    Fantini, Massimo Claudio
    Vecchi, Maurizio
    Geginat, Jens
    Caprioli, Flavio
    [J]. JOURNAL OF CROHNS & COLITIS, 2020, 14 (09): : 1190 - 1201
  • [23] Predictors of Clinical Response and Remission at 1 Year Among a Multicenter Cohort of Patients with Inflammatory Bowel Disease Treated with Vedolizumab
    Jessica R. Allegretti
    Edward L. Barnes
    Betsey Stevens
    Margaret Storm
    Ashwin Ananthakrishnan
    Vijay Yajnik
    Joshua Korzenik
    [J]. Digestive Diseases and Sciences, 2017, 62 : 1590 - 1596
  • [24] Predictors of Clinical Response and Remission at 1 Year Among a Multicenter Cohort of Patients with Inflammatory Bowel Disease Treated with Vedolizumab
    Allegretti, Jessica R.
    Barnes, Edward L.
    Stevens, Betsey
    Storm, Margaret
    Ananthakrishnan, Ashwin
    Yajnik, Vijay
    Korzenik, Joshua
    [J]. DIGESTIVE DISEASES AND SCIENCES, 2017, 62 (06) : 1590 - 1596
  • [25] Effect of obesity on vedolizumab response in inflammatory bowel disease
    Levine, Louis
    Gaidos, Jill K. J.
    Proctor, Deborah D.
    Viana, Artur V.
    Al-Bawardy, Badr
    [J]. ANNALS OF GASTROENTEROLOGY, 2022, 35 (03): : 275 - 280
  • [26] EFFECT OF OBESITY ON VEDOLIZUMAB RESPONSE IN INFLAMMATORY BOWEL DISEASE
    Levine, Louis
    Gaidos, Jill K.
    Proctor, Deborah D.
    Viana, Artur V.
    Al Bawardy, Badr
    [J]. GASTROENTEROLOGY, 2021, 160 (06) : S703 - S704
  • [27] Metabolomic predictors of response to vedolizumab in Inflammatory Bowel Disease
    Reider, S.
    Watschinger, C.
    Koch, R.
    Tilg, H.
    Moschen, A.
    [J]. JOURNAL OF CROHNS & COLITIS, 2024, 18 : I522 - I522
  • [28] Remission state in Inflammatory Bowel Disease patients on anti TNF or vedolizumab: a confocal endomicroscopy study
    Loly, J. P.
    Vieujean, S.
    Reenaers, C.
    Van Kemseke, C.
    Seidel, L.
    Somja, J.
    Louis, E.
    [J]. JOURNAL OF CROHNS & COLITIS, 2022, 16 : I283 - I283
  • [29] Combination therapy is not associated with improved rates of clinical or endoscopic remission in patients with inflammatory bowel disease treated with ustekinumab or vedolizumab: a retrospective study
    Jeffrey, Angus W.
    Picardo, Sherman
    Menon, Shankar
    So, Kenji
    Venugopal, Kannan
    [J]. ANNALS OF GASTROENTEROLOGY, 2023, 36 (04): : 430 - 436
  • [30] Vedolizumab dose escalation as a way of recapturing response in patients with inflammatory bowel disease
    Sierra Morales, M.
    Birdi, S.
    Samaan, M. A.
    Brown-Clarke, C.
    Duncan, J.
    Stanton, A.
    Koumoutsos, I.
    Anderson, S.
    Ray, S.
    Mawdsley, J.
    Sanderson, J.
    Irving, P. M.
    [J]. JOURNAL OF CROHNS & COLITIS, 2018, 12 : S451 - S452